RedHill Biopharma (RDHL) Net Cash Flow (2012 - 2022)

RedHill Biopharma (RDHL) has 11 years of Net Cash Flow data on file, last reported at $4.8 million in Q4 2022.

• On a quarterly basis, Net Cash Flow rose 76.19% year-over-year to $4.8 million in Q4 2022; TTM through Dec 2023 was $4.8 million, a 126.96% increase from a year earlier, with the FY2025 full-year figure at -$2.3 million, down 143.39% from the prior year.
• Net Cash Flow for Q4 2022 stood at $4.8 million, up from -$11.7 million in the prior quarter.
• Over the last five years, Net Cash Flow for RDHL reached as high as $48.5 million in Q1 2020 and fell as low as -$59.4 million in Q2 2020.
• Historically, Net Cash Flow has averaged -$1.4 million across 5 years, with a median of -$6.2 million in 2019.
• Across the five-year window, Net Cash Flow surged 727.8% in 2020 and sank 818.99% in 2021, its largest moves.
• Year by year, Net Cash Flow stood at $10.2 million in 2018, then surged by 118.77% to $22.2 million in 2019, then plunged by 121.43% to -$4.8 million in 2020, then jumped by 156.96% to $2.7 million in 2021, then jumped by 76.19% to $4.8 million in 2022.
• Per Business Quant data, the three most recent Net Cash Flow figures were $4.8 million in Q4 2022, -$11.7 million in Q3 2022, and -$1.7 million in Q2 2022.